Topical ruxolitinib for the treatment of alopecia universalis

JAMA Dermatology

Volumn 152, Issue 4, 2016, Pages 490-491

  Craiglow, Brittany G ^a   Tavares, Daniel ^b   King, Brett A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Quality Care Drug   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DITHRANOL; PREDNISONE; RUXOLITINIB; SALAZOSULFAPYRIDINE; SQUARIC ACID DIBUTYL ESTER; TRIAMCINOLONE; JANUS KINASE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ALOPECIA; ALOPECIA UNIVERSALIS; ARTICLE; CASE REPORT; CREAM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HAIR GROWTH; HUMAN; LEUKOCYTE COUNT; PRIORITY JOURNAL; SCANTY HAIR; ADOLESCENT; ANTAGONISTS AND INHIBITORS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ALOPECIA; FEMALE; HUMANS; JANUS KINASES; PROTEIN KINASE INHIBITORS; PYRAZOLES; TREATMENT OUTCOME;

EID: 84963718265     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.4445     Document Type: Article

References (3)

1. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988-2990.
2. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9): 1043-1049.
3. Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137-145.